BlueRock Therapeutics LP announced that the US FDA has granted Fast Track designation for DA01 for advanced Parkinson’s disease. DA01, BlueRock’s PSC-derived dopaminergic neuron therapy, is under evaluation in a Phase I study.
[BlueRock Therapeutics LP]
7992332
{7992332:nan}
apa
50
1
165185
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
